Mortality Down With GLP-1 Receptor Agonist Use in T2D, Especially in Those With OSA
Patients with type 2 diabetes mellitus (T2DM) prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have significantly lower 1-year mortality, especially those also diagnosed with obstructive sleep apnea (OSA).
A study presented at CHEST 2025, the annual meeting of the American College of Chest Physicians, found that GLP-1 RAs reduce one-year mortality in patients with T2DM, with a notable benefit in those with OSA.
- Cosmo Fowler, M.D., from Emory University in Atlanta, and colleagues examined data from the TriNetX U.S. Collaborative Network.
- A total of 1,799,261 patients with T2DM who were prescribed metformin were identified and stratified into different groups.
The study highlights the potential benefits of GLP-1 RAs in patients with T2DM, particularly those with OSA.
Author's summary: GLP-1 RAs reduce mortality in T2DM patients.